FDA Approves First Drug for Cold Agglutinin Disease

Sutimlimab-jome is the first drug to have FDA approval for the treatment cold agglutinin disease, a rare autoimmune hemolytic anemia in which antibodies destroy red blood cells.
FDA Approvals

source https://www.medscape.com/viewarticle/967966?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost